Cargando…
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes
Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents. Recently, everolimus, a mammalian target of rapamycin (mTOR) inhibitor, combined with exemesta...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000187/ https://www.ncbi.nlm.nih.gov/pubmed/24833916 http://dx.doi.org/10.2147/BCTT.S38679 |